• 3-Aminobenzamide (PARP-IN-1): Potent PARP Inhibitor Profile

  2026-06-17

  3-Aminobenzamide (PARP-IN-1) is a highly potent poly (ADP-ribose) polymerase inhibitor with an IC50 of ~50 nM in CHO cells. It effectively blocks PARP activity with low toxicity and demonstrates translational utility in oxidative stress and diabetic nephropathy models. This article aggregates evidence and protocol guidance for advanced research applications.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-16

  Schwartz's dissertation establishes a nuanced framework for evaluating anti-cancer drug responses in vitro by distinguishing between cell proliferation arrest and cell death. This approach enhances the predictive accuracy of preclinical assays and informs more effective cancer drug development strategies.

• L1023 Anti-Cancer Compound Library: High-Throughput Oncology

  2026-06-16

  The L1023 Anti-Cancer Compound Library empowers high-throughput, pathway-focused cancer research with ready-to-screen, cell-permeable inhibitors. Its curated diversity and robust format streamline target validation, mechanistic studies, and rapid drug discovery, providing a reliable foundation for translational breakthroughs.

• Optimizing mRNA Delivery with ARCA Cy5 EGFP mRNA (5-moUTP)

  2026-06-15

  This article addresses real-world laboratory challenges in mRNA delivery, localization, and translation efficiency, with a focus on ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009). Researchers will find evidence-based insights and protocol guidance on reliable quantification, immune evasion, and workflow integration, grounded in peer-reviewed literature and practical scenarios.

• Cell Counting Kit-8 (CCK-8): Precision in Cancer Cell Viabil

  2026-06-15

  The Cell Counting Kit-8 (CCK-8) delivers unmatched sensitivity and workflow simplicity for cell viability and cytotoxicity assays, especially in cancer research and mechanistic cell biology. Drawing on recent multi-omics studies and practical innovations, this guide demystifies protocol optimization and troubleshooting strategies that elevate experimental reproducibility.

• Linoleic Acid (C18:2): Technical Use and Workflow Best Pract

  2026-06-14

  Linoleic Acid (SKU C3108) enables precise modeling of membrane dynamics, oxidative stress, and essential fatty acid deficiency in cell-based and animal assays. It is not appropriate for protocols requiring water solubility or long-term stock solutions, but is optimal for workflows where fresh preparation and stringent solution handling are prioritized.

• GSK621 as a Precision AMPK Agonist: Redefining Immunometabol

  2026-06-13

  Explore how GSK621, a potent AMPK agonist, provides new depth for acute myeloid leukemia research and immunometabolic assay design. This article uniquely analyzes recent mechanistic advances and practical protocol insights, offering a differentiated perspective for translational scientists.

• Elobixibat Hydrate: Translational Leverage in GI and Metabol

  2026-06-12

  This article presents a thought-leadership perspective on Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, blending mechanistic insight with strategic advice for translational researchers. It critically integrates clinical performance, experimental workflow optimization, and competitive positioning. Drawing on robust primary literature and recent cross-domain advances, the discussion connects molecular action with new frontiers in metabolic and gastrointestinal research, offering actionable guidance for protocol design and future translational innovation.

• SGC-CBP30: Decoding CREBBP/EP300 Bromodomain Inhibition in E

  2026-06-12

  Explore the molecular mechanisms and advanced experimental strategies enabled by SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor. This article offers deep insights for epigenetics and cancer biology research, uniquely bridging reference breakthroughs with protocol optimization.

• Bromodomain Inhibitor, (+)-JQ1: Novel Insights in Disulfidpt

  2026-06-11

  Explore the unique properties and translational applications of Bromodomain Inhibitor, (+)-JQ1, a leading BET bromodomain inhibitor. This article delivers advanced guidance on integrating recent disulfidptosis discoveries into assay strategy, setting it apart from standard protocol or workflow guides.

• ALDOB K87 Lactylation Orchestrates Mitochondrial Fission in

  2026-06-11

  Yi et al. (2026) reveal that ALDOB K87 lactylation directly drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH), linking metabolic shifts to vascular pathology in smooth muscle cells. Their findings establish a lactate–ALDOB–DRP1 axis as a novel target for modulating abnormal PASMC proliferation and PH progression.

• IP3R/Ca2+/STAT3 Pathway Mediates Nanoplastic–Cadmium Apoptos

  2026-06-10

  This study uncovers how co-exposure to polystyrene nanoplastics and cadmium synergistically induces apoptosis in intestinal cells via the IP3R/Ca2+/STAT3 signaling axis. The mechanistic insights clarify environmental co-contaminant toxicity and provide a molecular foundation for targeted calcium signaling modulation in toxicology research.

• Alda 1: Unlocking ALDH2-Driven Cardiac Regeneration Pathways

  2026-06-10

  Explore how Alda 1, a leading ALDH2 activator, goes beyond cardioprotection by driving cardiomyocyte proliferation and regeneration. This article delivers new insights for researchers in cardiac ischemia, heart failure, and aldehyde detoxification.

• NSC 87877 Shp2 Inhibitor: Applied Workflows for Neuroinflamm

  2026-06-09

  NSC 87877 empowers researchers to selectively block the Shp2 signaling pathway, enabling precise mechanistic studies in neuroinflammation, cancer, and pain. This guide distills best practices, workflow enhancements, and troubleshooting strategies—leveraging the latest evidence to maximize the compound’s impact in experimental systems.

• USP7 Controls Macrophage Polarization via PKM2 in Pancreatit

  2026-06-09

  This study uncovers how ubiquitin-specific protease 7 (USP7) drives the pro-inflammatory polarization of macrophages in severe acute pancreatitis by regulating pyruvate kinase M2 (PKM2)-mediated metabolic reprogramming. The findings highlight the therapeutic potential of targeting PKM2 to modulate immune responses in inflammatory diseases.

446 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page